Impact of perioperative treatment on survival of resectable gastric cancer patients after D2 lymphadenectomy: a single European centre propensity score matching analysis
References
- Cats A, Jansen EPM, Grieken NCT, Sikorska K, Lind P, Nordsmark M, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet 2018; 19: 616-28. 10.1016/S1470-2045(18)30132-3
- Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatine for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-lable, randomised phase 3 trial. Lancet 2014; 15: 1389-96. 10.1016/S1470-2045(14)70473-5
- Reece-Smith AM, Saunders JH, Soomro IN, Bowman CR, Duffy JP, Kaye PV, et al. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma. Ann R Coll Surg Engl 2017; 99: 378-84. 10.1308/rcsann
- Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46. 10.1056/NEJMoa073149
- Yehou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicentre phase III trial. J Clin Oncol 2011; 29: 1715-21. 10.1200/JCO.2010.33.0597
- Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-20. 10.1056/NEJMoa0722
- Nakajima T, Fujii M. What make differences in the outcome in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol 2014; 20: 11567-73. 10.3748/wjg.v20.i33.11567
- Toneto MG, Viola L. Current status of the multidisciplinary treatment of gastric adenocarcinoma. [English, Portuguese]. Arq Bras Cir Dig 2018; 31: 1-4. 10.1590/0102-672020180001e1373
- Chuang J, Gong J, Klempner SJ, Woo Y, Chao J. Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. J Gastrointest Oncol 2018; 9: 560-72. 10.21037/jgo.2018.03.01
- Bose K, Franck C, Müller MN, Canbay A, Link A, Venerito M. Perioperative therapy of oesophagogastric adenocarcinoma and future directions. Gastroenterol Res Pract 2017; 1-6. 10.1155/2017/5651903
- Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet 2017; 18: 1249-60. 10.1016/S1470-2045(17)30447-3
- Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, DiCostanzo F, et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol 2014; 25: 1373-78. 10.1093/annonc/mdu146
- Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, et al. Phase III Trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol 2015; 33: 3130-3136. 10.1200/JCO.2014.58.3930
- Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30. 10.1056/NEJMoa010187
- Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-23. 10.1007/s10120-011-0042-4
- Oblak I, Skoblar Vidmar M, Anderluh F, Velenik V, Jeromen A, But Hadzic J. Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma. Radiol Oncol 2014; 48: 189-96. 10.2478/raon-2013-0065
- Lee KY, Noh SH, Hyung WJ, Lee JH, Lah KH, Choi SH, et al. Impact of splenectomy for lymph node dissection on long-term outcome in gastric cancer. Ann Surg Oncol 2001; 8: 402-6. PMID: 11407513
- Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrics 1983; 70: 41-55.
- Li M. Using the propensity score method to estimate causal effects: a review and practical guide. Organ Res Methods 2012; 00: 1-39. 10.1177/1094428112447816
- Hartgrink HH, van de Velde CJH, Putter H, Bonekamp JJ, Kranenbarg K, Songun I, et al. Extended lymph-node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol 2004; 22: 2069-77. 10.1200/JCO.2004.08.026
- Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AFY, et al. Nodal dissection for patients with gastric cancer: a randomized control trial. Lancet Oncol 2006; 7: 309-15. 10.1016/S1470-2045(06)70623-4
- Zhang Y, Tian S. Does D2 plus para-aortic nodal dissection surgery offer a better survival outcome compared to D2 surgery only for gastric cancer consistently? A definite result based on a hospital population of nearly two decades. Scand J Surg 2013; 102: 251-7. 10.1177/1457496913491343
Language: English
Page range: 245 - 255
Submitted on: Dec 12, 2018
Accepted on: Feb 24, 2019
Published on: May 8, 2019
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2019 Tomaz Jagric, Bojan Ilijevec, Vaneja Velenik, Janja Ocvirk, Stojan Potrc, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.